178 related articles for article (PubMed ID: 12085967)
1. The urokinase-type plasminogen activator system in prostate cancer metastasis.
Sheng S
Cancer Metastasis Rev; 2001; 20(3-4):287-96. PubMed ID: 12085967
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?
Fazioli F; Blasi F
Trends Pharmacol Sci; 1994 Jan; 15(1):25-9. PubMed ID: 8140655
[TBL] [Abstract][Full Text] [Related]
3. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
4. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
6. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
Kimura S; D'Andrea D; Iwata T; Foerster B; Janisch F; Parizi MK; Moschini M; Briganti A; Babjuk M; Chlosta P; Karakiewicz PI; Enikeev D; Rapoport LM; Seebacher V; Egawa S; Abufaraj M; Shariat SF
World J Urol; 2020 Oct; 38(10):2501-2511. PubMed ID: 31797075
[TBL] [Abstract][Full Text] [Related]
7. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of urokinase plasminogen activator receptor in prostate cancer cells derived from repeated metastasis.
Forbes K; Gillette K; Kelley LA; Sehgal I
World J Urol; 2004 Apr; 22(1):67-71. PubMed ID: 15052500
[TBL] [Abstract][Full Text] [Related]
9. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
10. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin.
Yoshida E; Verrusio EN; Mihara H; Oh D; Kwaan HC
Cancer Res; 1994 Jun; 54(12):3300-4. PubMed ID: 8205553
[TBL] [Abstract][Full Text] [Related]
13. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
14. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
15. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
16. Regulation and interactions in the activation of cell-associated plasminogen.
Myöhänen H; Vaheri A
Cell Mol Life Sci; 2004 Nov; 61(22):2840-58. PubMed ID: 15558213
[TBL] [Abstract][Full Text] [Related]
17. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Lyon PB; See WA; Xu Y; Cohen MB
Prostate; 1995 Oct; 27(4):179-86. PubMed ID: 7479384
[TBL] [Abstract][Full Text] [Related]
18. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies.
Rabbani SA; Xing RH
Int J Oncol; 1998 Apr; 12(4):911-20. PubMed ID: 9499455
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator.
Reinartz J; Schaefer B; Bechtel MJ; Kramer MD
Exp Cell Res; 1996 Feb; 223(1):91-101. PubMed ID: 8635500
[TBL] [Abstract][Full Text] [Related]
20. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Muehlenweg B; Sperl S; Magdolen V; Schmitt M; Harbeck N
Expert Opin Biol Ther; 2001 Jul; 1(4):683-91. PubMed ID: 11727504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
